Open access · CC-BY
via OpenAlex
An Updated Prioritization of Geroscience- Guided FDA-Approved Drugs Repurposed to Target Aging
Medical Research Archives · 2024 · ▲ 10 citations
Abstract
The biological mechanisms of aging drive the development of chronic diseases such as cardiovascular disease, diabetes, dementia, and cancer that dominate our current medical system. Geroscience-guided approaches seek to mitigate these pathological consequences of aging by targeting the fundamental telomere(definition) attrition, cellular senescence(definition))." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">hallmarks of aging(definition). Using modalities that modulate these aging mechanisms to reinforce longevity we can prevent the onset of these diseases as well as target many of them at once. In this way, geroscience-guided approaches hope to extend both lifespan and healthspan(definition) in the near future. This article builds upon a previous paper which proposed a standardized process for evaluating FDA-approved medications for their geroscience potential and prioritized them to reflect preclinical and clinical evidence. In this article, we provide an update of the previous list of candidate gerotherapeutics to reflect the new and rapidly evolving evidence. We include the geroscience-guided evidence for three new FDA-approved drugs which did not have strong arguments for inclusion before: bisphosphonates, GLP-1 receptor agonists, beta blockers. This updated prioritization should help guide the efforts and financial investments for translating geroscience and allow immediate progress involving such candidate gerotherapeutics, especially the top 4 drugs: SGLT2 inhibitors, metformin, bisphosphonates, and GLP-1 receptor agonists. Since all of these drugs have been approved for safety and used extensively, repurposing them as gerotherapeutics should be considered in older adults.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.18103/mra.v12i2.5138
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Leone, M., & Barzilai, N. (2024). An Updated Prioritization of Geroscience- Guided FDA-Approved Drugs Repurposed to Target Aging. <em>Medical Research Archives</em>. https://doi.org/10.18103/mra.v12i2.5138
Vancouver
Leone M, Barzilai N. An Updated Prioritization of Geroscience- Guided FDA-Approved Drugs Repurposed to Target Aging. Medical Research Archives. 2024. doi:10.18103/mra.v12i2.5138.
BibTeX
@article{michael2024AnUpda,
title = {An Updated Prioritization of Geroscience- Guided FDA-Approved Drugs Repurposed to Target Aging},
author = {Michael Leone and Nir Barzilai},
journal = {Medical Research Archives},
year = {2024},
doi = {10.18103/mra.v12i2.5138},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Innovation in Aging 2024
Open access · CC-BY
REPURPOSED FOR AGING
Aging Cell 2022
Open access · CC-BY
Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
Scholars' Bank (University of Oregon) 2025
Preprint · CC-BY
Sex Differences in the Response to Genetic and Chemical Pro-Longevity Interventions in Caenorhabditis elegans
Frontiers in Aging 2021
Open access · CC-BY
Network Topology of Biological Aging and Geroscience-Guided Approaches to COVID-19
Journal of Education Health and Sport 2026
Open access · CC-BY
Metformin as a Potential Geroprotective Agent: Mechanisms, Clinical Evidence and Implications for Healthy Aging
Journal of Xenobiotics 2026
Open access · CC-BY